SCHEMBL3374385

SCHEMBL3374385

CCNC(=O)c1ccc(C(N)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.56
NR1H4 Q96RI1 1/20 0.56
PARP10 Q53GL7 2/20 0.50
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
HDAC4 P56524 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
KMT2A Q03164 3/20 0.47
LMNA P02545 3/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
PARP1 P09874 1/20 0.45
PARP2 Q9UGN5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5909057 0.89 CA12 (0.58) CA12CA9HDAC4HDAC6KMT2A
SCHEMBL9625469 0.85 MPO (0.59) CA12CA9KMT2ALMNAMEN1
SCHEMBL2977016 0.84 KDM4E (0.65) EPHX2NR1H4KMT2ALMNAKDM4E
SCHEMBL854839 0.83 MAPT (0.63) EPHX2CA12CA9HDAC4HDAC6
SCHEMBL17299368 0.83 CA12 (0.50) CA12CA9HDAC4HDAC6KMT2A
SCHEMBL15168443 0.83 LMNA (0.55) EPHX2NR1H4HDAC4HDAC6KMT2A
SCHEMBL26246561 0.82 EPHX2 (0.54) EPHX2NR1H4PARP10KMT2ALMNA
SCHEMBL45720 0.81 SMN1; SMN2 (0.57) KMT2AMEN1SMN1; SMN2PARP1ALDH1A1
SCHEMBL2967223 0.81 L3MBTL1 (0.63) EPHX2KMT2AKDM4ESMN1; SMN2NPC1
SCHEMBL92285 0.81 GFER (0.59) CA12CA9HDAC4HDAC6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354444-B2 Substituted pyrrolidine-2-carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-01-15 US claimed
CN-102403478-A Production method of high-permeability low-density lithium battery polyolefin diaphragm TONGLING JINGNENG ELECTRONIC CO LTD 2012-04-04 CN claimed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US claimed
EP-2188289-A2 (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION Lexicon Pharmaceuticals, Inc. (US) 2010-05-26 EP claimed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US claimed
WO-2009021169-A2 (7H-PYRR0L0 [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION LEXICON PHARMACEUTICALS, INC. (US) 2009-02-12 WO claimed
CN-116768763-B Preparation method and application of alicyclic carbamate 中国科学院过程工程研究所 2026-02-27 CN disclosed
WO-2017136659-A2 HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2017-08-10 WO disclosed
WO-2017105985-A1 PREPARATION OF ISOHEXIDE-3,6-DICARBALDEHYDES AND ISOHEXIDE-3,6-DIMETHANAMINES ARCHER DANIELS MIDLAND COMPANY (US) 2017-06-22 WO disclosed
EP-2534132-B1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2017-04-26 EP disclosed
EP-2188289-B1 (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION LEXICON PHARMACEUTICALS INC (US) 2015-10-28 EP disclosed
WO-2014153164-A1 TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2014-09-25 WO disclosed
EP-2597098-A1 (7H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION Lexicon Pharmaceuticals, Inc. (US) 2013-05-29 EP disclosed
CN-102403478-A Production method of high-permeability low-density lithium battery polyolefin diaphragm TONGLING JINGNENG ELECTRONIC CO LTD 2012-04-04 CN disclosed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US disclosed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US disclosed
US-20080058525-A1 NOVEL DYE COMPLEXES AND USE THEREOF IN IMAGING MEMBERS AND METHODS ZINK IMAGING, LLC 2008-03-06 US disclosed
US-7282317-B2 Dye complexes and use thereof in imaging members and methods ZINK IMAGING, LLC (US) 2007-10-16 US disclosed
EP-1200504-A2 POLYMERISATION METHOD Cambridge Display Technology Limited (GB) 2002-05-02 EP disclosed
WO-2001007502-A2 POLYMERISATION METHOD CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 EPHX2 2619/4885NR1H4 3323/4885PARP10 74/4885
US-20080058525-A1 NOVEL DYE COMPLEXES AND USE THEREOF IN IMAGING MEMBERS AND METHODS DBI, HSPE1, ABCB7 EPHX2 2853/4885NR1H4 1342/4885PARP10 1567/4885
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 EPHX2 2619/4885NR1H4 3323/4885PARP10 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.